Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Retained Earnings: 2011-2025

Historic Retained Earnings for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$721.6 million.

  • Abeona Therapeutics' Retained Earnings rose 10.25% to -$721.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$721.6 million, marking a year-over-year increase of 10.25%. This contributed to the annual value of -$813.3 million for FY2024, which is 8.50% down from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Retained Earnings is -$721.6 million, which was down 0.72% from -$716.5 million recorded in Q2 2025.
  • Abeona Therapeutics' Retained Earnings' 5-year high stood at $688.2 million during Q3 2022, with a 5-year trough of -$825.3 million in Q1 2025.
  • Its 3-year average for Retained Earnings is -$758.5 million, with a median of -$749.5 million in 2023.
  • In the last 5 years, Abeona Therapeutics' Retained Earnings skyrocketed by 213.02% in 2022 and then tumbled by 206.50% in 2023.
  • Over the past 5 years, Abeona Therapeutics' Retained Earnings (Quarterly) stood at -$655.6 million in 2021, then declined by 6.05% to -$695.3 million in 2022, then fell by 7.79% to -$749.5 million in 2023, then declined by 8.50% to -$813.3 million in 2024, then climbed by 10.25% to -$721.6 million in 2025.
  • Its Retained Earnings stands at -$721.6 million for Q3 2025, versus -$716.5 million for Q2 2025 and -$825.3 million for Q1 2025.